---
document_datetime: 2023-09-21 19:10:03
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/forcaltonin-epar-procedural-steps-taken-authorisation_en.pdf
document_name: forcaltonin-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.3839764
conversion_datetime: 2025-12-14 23:41:34.115512
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
<!-- image -->

Medicinal product no longer authorised 1/1  EMEA 2005 BACKGROUND INFORMATION ON THE PROCEDURE 1. Submission of the dossier The  company  Unigene  UK  Limited  submitted  on  22  August  1997  an  application  for  Marketing Authorisation  to  the  European  Agency  for  the  Evaluation  of  Medicinal  Products  (EMEA)  for Forcaltonin,  in  accordance  with  the  centralised  procedure  falling  within  the  scope  of  Part  A  of  the Annex to Council Regulation No (EEC) 2309/93 of 22 July 1993. The Rapporteur and Co-Rapporteur appointed by the CPMP were: Rapporteur: Prof. Hildebrandt Co-Rapporteur: D. M. Teeling Licensing status: Forcaltonin was not licensed in any country inside or outside the EU at the time of submission of the application. 2. Steps taken for the assessment of the product · The procedure started on 26 September 1997 · The Rapporteur's first assessment report was circulated to all CPMP Members on 5 December 1997. The Co-Rapporteur's first assessment report was circulated to all CPMP Members on 8 December 1997. · Comments on points not covered by the Assessment report were due on 6 January 1998. · During the meeting on 27 January 1998 the CPMP agreed on the consolidated list of questions to be sent to the company. The final consolidated list of questions was sent to the company on 27 January 1998. · The company submitted the responses to the consolidated list of questions on 20 July 1998 · The Rapporteur and the Co-Rapporteur circulated the joint response assessment report on the company's responses to the list of questions to all CPMP Members on 28 August 1998. · At  the  beginning  of  September  1998,  the  company  submitted  to  all  CPMP  Members  an expanded data set on the alpha-amidating enzyme (AE). The Rapporteur circulated an analysis of the data set on 10 September 1998. · During  the  meeting  on  15-17  September  1998  the  CPMP,  in  the  light  of  the  overall  data submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for granting a Marketing Authorisation to Forcaltonin on 17 September 1998. · The CPMP opinions were forwarded, in all official languages of the European Union, to the European Commission, which adopted the corresponding Decisions on 11 January 1999. II